Data updated: Mar 10, 2026
DOFETILIDE
DOFETILIDE
Approved 2016-06-06
11
Indications
--
Phase 3 Trials
9
Years on Market
Details
- Status
- Discontinued
- First Approved
- 2016-06-06
- Routes
- ORAL
- Dosage Forms
- CAPSULE
Companies
Teva PRINSTON INC GRANULES BIONPHARMA Dr. Reddy's SIGMAPHARM LABS LLC ACCORD HLTHCARE STRIDES PHARMA INTL RK PHARMA MSN Sun Pharma INGENUS PHARMS LLC
Active Ingredient: DOFETILIDE
Website: ↗
DOFETILIDE Approval History
Loading approval history...
What DOFETILIDE Treats
11 FDA approvalsOriginally approved for its first indication in 2016 . Covers 11 distinct patient populations.
- Other (11)
Other
(11 approvals)- • Approved indication (Jun 2016)Label Letter
- • Approved indication (Mar 2018)
- • Approved indication (Apr 2018)
- • Approved indication (Oct 2018)
- • Approved indication (Dec 2019)
- • Approved indication (Dec 2019)
- • Approved indication (Jan 2020)
- • Approved indication (Jun 2020)
- • Approved indication (Oct 2021)
- • Approved indication (Apr 2022)
- • Approved indication (Apr 2022)
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
DOFETILIDE FDA Label Details
ProWant competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.